Incyte | INCY - DEBITO





DEBITO Cambiamento Data
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agenus USD 35.54M 2.34M 2025-03
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amgen USD 54.6B 17M 2025-12
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Biogen USD 6.56B 275.1M 2026-03
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Eli Lilly USD 42.5B 3.6M 2025-12
Exelixis USD 169.54M 3.5M 2026-03
Gilead Sciences USD 24.94B 5M 2025-12
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
MacroGenics USD 37.01M 238K 2025-09
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 47B 11.62B 2026-03
Novartis USD 32.02B 615M 2025-09
Pfizer USD 63.73B 231M 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.99B 44M 2026-03